Compare Adaptive Biotechnologies Corp (ADPT) vs Gitlab Inc (GTLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Gitlab Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Gitlab Inc trades at $31.77 (market cap $5.50B). The key difference: Gitlab Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | GTLB | |
|---|---|---|
Market Cap | $3.33B | $5.50B |
Sector | Health | Technology |
52-Week High | $22.37 | $51.04 |
52-Week Low | $10.24 | $19.42 |
Enterprise Value | $3.19B | $4.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GitLab (GTLB) trades at $32.59, up 1.62% today, with a bullish technical signal and recent earnings beats. The stock shows strong revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net margin. Analyst sentiment is mixed, with a consensus price target of $31.86, while recent news highlights its leadership in DevSecOps and AI-driven software development.
Outlook: GitLab's growth trajectory and strategic position in AI and DevSecOps present upside potential, but profitability concerns and high valuation ratios pose risks. Investors should weigh strong revenue expansion against ongoing losses and competitive pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
